Certa Therapeutics represented at Biotechnology Innovation Organisation (BIO) International Convention in Boston

Melbourne, Australia, 05 June 2023: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, announced today that its Executive Chair, Professor Darren Kelly and Chief Commercial Officer, Dr Gareth Lewis, will be attending the 2023 Biotechnology Innovation Organisation International Convention (BIO) from 5-8 June in Boston.  

During the convention, the Certa team will highlight their innovative scientific advancements including their ongoing clinical development program for the lead candidate FT011 and the mechanism of action for the drugs in the treatment of inflammatory and fibrotic diseases.

“We’re excited to attend this year’s BIO Convention and looking forward to continuing our discussions with pharmaceutical partners and other biotechnology investment firms about recent scientific advancements and the clinical development program for our lead candidate FT011” said Professor Darren Kelly, CEO of Certa Therapeutics.

The BIO 2023 convention attracts more than 14,000 biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.